Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-label, Non-randomized, Single Ascending Dose Escalation Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of A Ralinepag Extended Release (XR) Tablet Formulation In Healthy Chinese Subjects

NCT04613999 is registered in ClinicalTrials.gov with Everstar Medicines (Shanghai) Limited as lead sponsor.

NCT NCT04613999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04613999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-label, Non-randomized, Single Ascending Dose Escalation Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of A Ralinepag Extended Release (XR) Tablet Formulation In Healthy Chinese Subjects
Lead sponsor
Everstar Medicines (Shanghai) Limited
Phase
Phase 1
Overall status
Completed
Start date
October 9, 2020
Completion date
November 9, 2020
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteer, pharmacokinetic study